Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment

Since the COVID-19 pandemic, cancer patients have been recognized as a group with an increased risk of complications, if they become infected with the SARS-CoV-2 virus. However, they were not included in registrational trials for COVID-19 vaccines. In the last few months data from studies investiga...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tina Zupančič, Cvetka Kuhar Grašič
Formato:	article
Lenguaje:	SL
Publicado:	Institute of Oncology Ljubljana 2021
Materias:	vaccination against COVID-19 cancer patients humoral response cellular response safety Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/88e12c42dff240bfa773b79412dac2c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:88e12c42dff240bfa773b79412dac2c8
record_format	dspace
spelling	oai:doaj.org-article:88e12c42dff240bfa773b79412dac2c82021-12-04T20:23:55ZEfficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment10.25670/oi2021-016on1408-17411581-3215https://doaj.org/article/88e12c42dff240bfa773b79412dac2c82021-11-01T00:00:00Zhttps://revijaonkologija.si/Onkologija/article/view/484https://doaj.org/toc/1408-1741https://doaj.org/toc/1581-3215 Since the COVID-19 pandemic, cancer patients have been recognized as a group with an increased risk of complications, if they become infected with the SARS-CoV-2 virus. However, they were not included in registrational trials for COVID-19 vaccines. In the last few months data from studies investigating the efficacy and safety of COVID-19 vaccines in cancer patients receiving systemic treatment have become available. It has been established that the efficacy (regarding humoral and cellular response) and safety of COVID-19 vaccines in solid cancer patients are comparable to that in healthy individuals. On the other side, humoral response is very low or even undeterminable in haematological patients, especially in those receiving anti-CD 20+ targeted therapy or Bruton kinase inhibitors. However, a cellular response is preserved and vaccination, including with a third dose, is reasonable. Cancer patients who were infected with SARS-CoV-2 and then vaccinated developed much better humoral response. Tina ZupančičCvetka Kuhar GrašičInstitute of Oncology Ljubljanaarticlevaccination against COVID-19cancer patientshumoral responsecellular responsesafetyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282SLOnkologija, Vol 25, Iss 2 (2021)
institution	DOAJ
collection	DOAJ
language	SL
topic	vaccination against COVID-19 cancer patients humoral response cellular response safety Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	vaccination against COVID-19 cancer patients humoral response cellular response safety Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Tina Zupančič Cvetka Kuhar Grašič Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
description	Since the COVID-19 pandemic, cancer patients have been recognized as a group with an increased risk of complications, if they become infected with the SARS-CoV-2 virus. However, they were not included in registrational trials for COVID-19 vaccines. In the last few months data from studies investigating the efficacy and safety of COVID-19 vaccines in cancer patients receiving systemic treatment have become available. It has been established that the efficacy (regarding humoral and cellular response) and safety of COVID-19 vaccines in solid cancer patients are comparable to that in healthy individuals. On the other side, humoral response is very low or even undeterminable in haematological patients, especially in those receiving anti-CD 20+ targeted therapy or Bruton kinase inhibitors. However, a cellular response is preserved and vaccination, including with a third dose, is reasonable. Cancer patients who were infected with SARS-CoV-2 and then vaccinated developed much better humoral response.
format	article
author	Tina Zupančič Cvetka Kuhar Grašič
author_facet	Tina Zupančič Cvetka Kuhar Grašič
author_sort	Tina Zupančič
title	Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
title_short	Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
title_full	Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
title_fullStr	Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
title_full_unstemmed	Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
title_sort	efficacy (and safety) of vaccination against sars-cov-2 in cancer patients on active treatment
publisher	Institute of Oncology Ljubljana
publishDate	2021
url	https://doaj.org/article/88e12c42dff240bfa773b79412dac2c8
work_keys_str_mv	AT tinazupancic efficacyandsafetyofvaccinationagainstsarscov2incancerpatientsonactivetreatment AT cvetkakuhargrasic efficacyandsafetyofvaccinationagainstsarscov2incancerpatientsonactivetreatment
_version_	1718372684540149760

Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment

Ejemplares similares